Aurobindo Pharma inks voluntary license with Medicines Patent Pool

31 Mar 2023 Evaluate

Aurobindo Pharma has signed voluntary sub-licensing with Medicines Patent Pool (MPP), a UN organization, for developing and marketing Cabotegravir Tablets & Long Acting Injectables, originally developed by ViiV Healthcare, for the prevention of HIV in 90 Low and Middle-Income Countries (LMIC), including India.

For the generic version of Cabotegravir, Aurobindo will utilize their vertically integrated capabilities to develop in-house API manufacturing which will enable stronger control on supply chain and cost efficiencies. The tablet and injectable dosage forms of the product will be produced at the APL Healthcare Unit IV, Naidupet, India, and at the new Eugia Sterile facility, Vizag, India, respectively. The company has adequate capacities of world class standards, to meet the global demand for the product across the licensed territory.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1172.30 -7.95 (-0.67%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×